Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for GDC-0032

4 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBRE1374

    06/15/2015

    Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination with Enzalutamide in Patients with Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    VICCBRE1320

    08/16/2013

    A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

    Treatment

    VICCPHI1248

    10/12/2012

    An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer


    Print this page for your doctor